Palisade Bio, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Palisade Bio is a pre-clinical biotechnology company developing therapeutics for autoimmune, inflammatory, and fibrotic diseases. Its lead and only actively developed product candidate is PALI-2108, a colon-targeted PDE4 inhibitor for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. The filing covers the quarter ended March 31, 2024 and was filed May 13, 2024.
The company discontinued development of LB1148 in August 2023 and is shifting resources toward PALI-2108. The financial statements are unaudited and prepared under U.S. GAAP.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| License revenue | $0 | $250,000 | Down $250,000 |
| Research and development expense | $2.214 million | $1.241 million | Up 78% |
| General and administrative expense | $1.459 million | $1.538 million | Down 5% |
| Total operating expenses | $3.673 million | $2.779 million | Up 32% |
| Loss from operations | $3.673 million | $2.529 million | Higher loss |
| Net loss | $3.527 million | $2.340 million | Up 51% |
| Net loss per share | $4.59 | $8.13 | Improved; reverse-split adjusted |
| Net cash used in operating activities | $3.180 million | $3.526 million | Lower use of cash |
| Net cash from financing activities | $2.024 million | $4.440 million | Down $2.416 million |
As of March 31, 2024, cash and cash equivalents were $11.276 million, restricted cash was $26,000, and total assets were $12.652 million. Total liabilities were $2.588 million, including a $204,000 contingent consideration obligation and $183,000 of operating lease liabilities. The company had no outstanding insurance financing debt at quarter-end.
Accumulated deficit was $125.033 million. The company has no product sales and expects continuing operating losses. No meaningful operating margin or profitability was reported.
Material Changes Versus the Prior Comparable Period
- License revenue fell to zero from $250,000, reflecting the absence of a Newsoara development milestone recognized in Q1 2023.
- Research and development expense increased by approximately $973,000, primarily due to approximately $1.6 million of PALI-2108 joint-development expenses under the Giiant agreement. Lower LB1148 clinical costs and reduced employee costs partially offset the increase.
- General and administrative expense was broadly stable, with higher shareholder-service and consulting costs offset by lower professional fees, insurance costs, and director fees.
- Operating cash burn improved to $3.180 million from $3.526 million, largely due to working-capital timing and higher accrued joint-development expenses.
- On February 1, 2024, holders exercised 228,162 existing warrants at a reduced exercise price of $10.97 per share. The transaction generated approximately $2.2 million of net proceeds and issued replacement warrants.
- The company effected a 1-for-15 reverse stock split on April 5, 2024. Q1 share and per-share data have generally been retrospectively adjusted for the split.
- Common shares issued and outstanding increased from 618,056 at December 31, 2023 to 851,302 at March 31, 2024, before subsequent financing activity.
Guidance, Outlook, Risks, and Unusual Items
- Management expects pivotal IND/CTA-enabling pre-clinical studies for PALI-2108 to be completed by the end of Q3 2024, with an IND/CTA submission and initiation of a Phase 1a SAD/MAD study planned for Q4 2024.
- Topline Phase 1a data is expected in late H1 2025, followed by a planned Phase 1b/2 proof-of-concept study in ulcerative colitis in H2 2025.
- Management believes cash on hand at March 31, 2024, together with the subsequent May financing, is sufficient to fund currently planned operations through Q1 2025. Additional financing will be required thereafter and potentially sooner if operating plans change.
- The financial statements disclose substantial doubt about the company’s ability to continue as a going concern for one year after issuance. Future funding may require equity offerings, debt, collaborations, or licensing transactions and could materially dilute shareholders.
- On May 6, 2024, after quarter-end, the company completed a private placement generating approximately $3.6 million of net proceeds. The financing included common stock, prefunded warrants, and long-term common stock warrants.
- The company recognized approximately $1.6 million of Q1 expenses related to joint development with Giiant and had accrued approximately $1.2 million of related expenses at March 31, 2024. The Giiant license includes milestone payments, royalties, and termination provisions.
- As of March 31, 2024, the company reported a continuing material weakness in internal control over financial reporting. Disclosure controls and procedures were therefore considered ineffective at a reasonable assurance level.
- Nasdaq had notified the company that its audit committee lacked three independent members. The company appointed an additional director on May 7, 2024, but had not yet received confirmation from Nasdaq that the deficiency was cured as of the filing date.
- Key operating risks include the pre-clinical status of PALI-2108, uncertain regulatory and clinical outcomes, reliance on Giiant and third-party contractors, intellectual-property and license risks, limited liquidity, potential dilution, Nasdaq listing compliance, and cybersecurity and market risks.
Most Important Facts for Investors to Verify
- Whether the planned PALI-2108 IND/CTA submission and Q4 2024 Phase 1a initiation remain on schedule.
- The company’s cash runway after the May 2024 financing, current quarterly burn rate, and timing and terms of the next required capital raise.
- Whether the going-concern uncertainty has been resolved or remains disclosed in subsequent filings.
- Whether the material weakness in internal controls has been remediated and independently tested.
- Whether Nasdaq confirms that the audit committee composition deficiency has been cured and whether other listing requirements remain satisfied.
- The dilution and potential overhang from approximately 285,891 exercisable warrants outstanding at March 31, 2024, plus the securities issued in May 2024.
- The status, cost, and deliverables under the Giiant license and joint-development arrangement, including milestone and royalty obligations.
- Whether pre-clinical efficacy, safety, bioactivation, and biomarker findings for PALI-2108 translate into successful human clinical results.